SG11201807040WA - N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer - Google Patents
N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancerInfo
- Publication number
- SG11201807040WA SG11201807040WA SG11201807040WA SG11201807040WA SG11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- quinolin
- imidazo
- propan
- pyridyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201605958 | 2016-04-07 | ||
PCT/EP2017/057624 WO2017174446A1 (en) | 2016-04-07 | 2017-03-30 | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807040WA true SG11201807040WA (en) | 2018-09-27 |
Family
ID=58461335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807040WA SG11201807040WA (en) | 2016-04-07 | 2017-03-30 | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190119270A1 (de) |
EP (1) | EP3440079A1 (de) |
JP (1) | JP2019513730A (de) |
KR (1) | KR20180132804A (de) |
CN (1) | CN108834414A (de) |
AU (1) | AU2017247558A1 (de) |
BR (1) | BR112018070229A2 (de) |
CA (1) | CA3015953A1 (de) |
EA (1) | EA201891866A1 (de) |
IL (1) | IL261558A (de) |
MA (1) | MA44603A (de) |
MX (1) | MX2018012255A (de) |
SG (1) | SG11201807040WA (de) |
WO (1) | WO2017174446A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
TW202216209A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atm抑制劑之組合 |
EP3992191A1 (de) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]chinolin-verbindungen und deren verwendung als atm-kinase-inhibitoren |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
CN103030637A (zh) * | 2011-10-10 | 2013-04-10 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
NO2714752T3 (de) | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-30 CA CA3015953A patent/CA3015953A1/en not_active Abandoned
- 2017-03-30 EP EP17714741.0A patent/EP3440079A1/de not_active Withdrawn
- 2017-03-30 KR KR1020187031898A patent/KR20180132804A/ko unknown
- 2017-03-30 AU AU2017247558A patent/AU2017247558A1/en not_active Abandoned
- 2017-03-30 CN CN201780019968.0A patent/CN108834414A/zh active Pending
- 2017-03-30 BR BR112018070229A patent/BR112018070229A2/pt not_active Application Discontinuation
- 2017-03-30 MA MA044603A patent/MA44603A/fr unknown
- 2017-03-30 JP JP2018552177A patent/JP2019513730A/ja active Pending
- 2017-03-30 US US16/091,542 patent/US20190119270A1/en not_active Abandoned
- 2017-03-30 MX MX2018012255A patent/MX2018012255A/es unknown
- 2017-03-30 WO PCT/EP2017/057624 patent/WO2017174446A1/en active Application Filing
- 2017-03-30 SG SG11201807040WA patent/SG11201807040WA/en unknown
- 2017-03-30 EA EA201891866A patent/EA201891866A1/ru unknown
-
2018
- 2018-09-03 IL IL261558A patent/IL261558A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3015953A1 (en) | 2017-10-12 |
JP2019513730A (ja) | 2019-05-30 |
MA44603A (fr) | 2019-02-13 |
CN108834414A (zh) | 2018-11-16 |
MX2018012255A (es) | 2019-02-07 |
IL261558A (en) | 2018-10-31 |
US20190119270A1 (en) | 2019-04-25 |
EP3440079A1 (de) | 2019-02-13 |
EA201891866A1 (ru) | 2019-04-30 |
WO2017174446A1 (en) | 2017-10-12 |
KR20180132804A (ko) | 2018-12-12 |
AU2017247558A1 (en) | 2018-09-13 |
BR112018070229A2 (pt) | 2019-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201901716TA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201807040WA (en) | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer | |
SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors |